Home › MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research
 

Keywords :   


MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research

2016-01-16 23:09:46| Biotech - Topix.net

The brokerage presently has a $1.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 7.71% from the company's current price.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Eastern North Pacific Tropical Weather Outlook
05.10Atlantic Tropical Weather Outlook
05.10Weekly Recap: BASF, Beckers, Allnex, Sherwin-Williams Top This Weeks Stories
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 24
05.10Hurricane Kirk Wind Speed Probabilities Number 24
05.10Hurricane Kirk Forecast Advisory Number 24
05.10Hurricane Kirk Public Advisory Number 24
More »